Noveome Biotherapeutics, Inc. Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cells

PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical
company focused on developing next-generation biologics for the
promotion and restoration of cellular integrity of inflamed or damaged
tissues, today announced the publication of preclinical results for
ST266, its proprietary, cell-free platform biologic, published in the Journal
of Neuro-Ophthalmology. These new results further support the
neuroprotective properties of intranasally delivered ST266 in mice with
experimental autoimmune encephalomyelitis (EAE)-induced experimental
optic neuritis (ON).

The publication entitled, “Effects of Varying Intranasal Treatment
Regimens in ST266-Mediated Retinal Ganglion Cell Neuroprotection,”
details the preclinical study exploring the neuroprotective effects of
daily and twice daily intranasally delivered ST266 to evaluate different
treatment regimens an EAE-induced experimental ON mouse model.

“In previous studies, we showed that a single daily dose of
ST266 administered through the nose diminished visual dysfunction,
prevented retinal ganglion cell loss, and reduced both inflammation and
demyelination six weeks after induction of EAE,” said Larry Brown,
Sc.D., Noveome’s Chief Scientific Officer.

Kenneth S. Shindler, M.D., Ph.D., an associate professor of
Ophthalmology in the Perelman School of Medicine at the University of
Pennsylvania and Penn’s Scheie Eye Institute, and senior author on the
paper continued, “In this study we demonstrated the ability of ST266 to
confer longer-term neuroprotective effects, by showing that EAE mice
that received either once or twice daily intranasal drops of ST266
starting from day 15 and repeated through day 56 showed significant
preservation of vision, significant preservation of retinal ganglion
cells, and significant reduction in optic nerve inflammation.”

“We are pleased to see these strong preclinical results that further
validate this approach to non-cellular therapeutic treatment for optic
nerve diseases. These results demonstrate the promise of our novel
platform biologic, in which the multiple growth factors and
anti-inflammatory cytokines present in ST266 are able to achieve
neuroprotective benefits in varying intranasal treatment regimens,” said
William J. Golden, Founder, Chairman and Chief Executive Officer of
Noveome. “With this foundational science in hand, we look forward to
further exploring ST266’s neuroprotective properties in our growing CNS
pipeline with data from our Phase 1 clinical trial of intranasal ST266
in patients at risk of developing optic nerve disease expected later
this year.”

About Noveome Biotherapeutics, Inc.

Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing next-generation biologics for the
promotion and restoration of cellular integrity of inflamed or damaged
tissues. Noveome’s multi-target platform biologic and lead product,
ST266, is a complex, non-cellular product containing hundreds of
biologically active proteins and other biologic factors. ST266 is
currently being evaluated in multiple indications across CNS,
ophthalmic, pulmonary and gastrointestinal therapeutic areas. Topline
data from an ongoing Phase 1 trial using a novel intranasal delivery
method to deliver ST266 to the optic nerve and brain and an ongoing
Phase 2 trial in corneal defects are expected later in 2019. In
addition, preclinical results testing ST266 in chronic traumatic
encephalopathy, emphysema and necrotizing enterocolitis are also
expected later in 2019. The Company received seed funding from Lancet
Capital, a venture capital consortium of leading Pittsburgh healthcare
institutions including UPMC Enterprises, Highmark Blue Cross/Blue
Shield, University of Pittsburgh and Carnegie Mellon University. To
date, Noveome has received over $120 million in research and
infrastructure funding from the U.S. Department of Defense, the
Commonwealth of Pennsylvania and Allegheny County. Noveome is based in
Pittsburgh, PA. For more information, please visit, www.noveome.com.

Contacts

Investor:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
[email protected]